Fulton Bank N.A. Acquires 11,702 Shares of Medtronic PLC $MDT

Posted by Francis Steltz on Aug 12th, 2026

Fulton Bank N.A. increased its holdings in Medtronic PLC (NYSE:MDT – Free Report) by 65.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,675 shares of the medical technology company’s stock after acquiring an additional 11,702 shares during the period. Fulton Bank N.A.’s holdings in Medtronic were worth $2,321,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in MDT. Anfield Capital Management LLC boosted its stake in Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 230 shares during the last quarter. Monetary Solutions Ltd purchased a new stake in shares of Medtronic in the fourth quarter worth approximately $27,000. Acumen Wealth Advisors LLC purchased a new stake in shares of Medtronic in the fourth quarter worth approximately $29,000. Imprint Wealth LLC bought a new position in shares of Medtronic in the third quarter valued at approximately $31,000. Finally, Basepoint Wealth LLC bought a new position in shares of Medtronic in the fourth quarter valued at approximately $32,000. Institutional investors own 82.06% of the company’s stock.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Analyst upgrades reinforce the turnaround thesis. UBS upgraded Medtronic to Buy from Neutral, citing evidence that a turnaround is underway. Additional analyst upgrades point to the company’s strongest annual revenue growth in roughly a decade, driven by its cardiac portfolio and new product launches. Medtronic Wins Analyst Upgrades, Is It Fully Priced?
Positive Sentiment: Options activity signals increased bullish interest. Investors purchased 19,654 MDT call options, 56% above typical daily call volume. While this is speculative rather than a fundamental measure, it suggests rising short-term trader interest.
Positive Sentiment: Growth opportunities remain substantial in cardiac care. A new industry report projects the global pulsed-field ablation market to grow from approximately $3.2 billion in 2026 to $14.6 billion by 2035. Medtronic is listed among the major competitors that could benefit from expanding adoption of the technology. Pulsed Field Ablation Global Market Report 2026
Positive Sentiment: Pipeline collaboration is progressing. Orchestra BioMed said its BACKBEAT pivotal trial, conducted with Medtronic, remains on track to reach its enrollment target by the end of the third quarter, with primary data expected in the second quarter of 2027. Successful results could create an additional future growth driver. Orchestra BioMed Reports Second Quarter Results
Neutral Sentiment: Valuation is becoming a key investor question. After its recent advance, investors are assessing whether Medtronic’s improving outlook is already reflected in the share price. The company’s forward growth, dividend support and FY2027 EPS guidance of $5.90–$6.00 provide fundamental support, but continued gains may require evidence that the recovery is sustainable.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.26% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MDT. TD Cowen decreased their price target on Medtronic from $119.00 to $100.00 and set a “buy” rating for the company in a report on Friday, July 10th. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Sanford C. Bernstein cut their price objective on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a report on Thursday, June 4th. UBS Group raised shares of Medtronic from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $85.00 to $100.00 in a report on Tuesday, July 28th. Finally, Leerink Partners reduced their target price on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a research note on Thursday, June 4th. Eighteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $98.83.

Read Our Latest Stock Analysis on Medtronic

Medtronic Stock Performance

Shares of MDT stock opened at $90.55 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The firm has a market cap of $115.91 billion, a price-to-earnings ratio of 24.28, a P/E/G ratio of 2.40 and a beta of 0.55. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The firm’s 50-day simple moving average is $82.59 and its two-hundred day simple moving average is $86.48.

Medtronic (NYSE:MDT – Get Free Report) last released its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. During the same period in the prior year, the firm earned $1.62 EPS. The company’s revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities analysts forecast that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Shareholders of record on Friday, June 26th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 3.2%. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date of this dividend was Friday, June 26th. Medtronic’s dividend payout ratio is currently 77.21%.

Medtronic Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).